Mimix™ Prostate Cancer Panel cfDNA Reference Standard
The Prostate Cancer Panel cfDNA Reference Standard is a well characterized, cell line-derived control material manufactured under ISO:13485 that contains 17 variants (including 2 CNVs) across 9 genes clinically relevant to prostate cancer.
The Prostate Cancer Panel cfDNA Reference Standard is a well characterized, cell line-derived control material manufactured under ISO:13485 that contains 17 variants across 9 genes clinically relevant to prostate cancer. This exciting new Multigene Multiplex product allows labs to perform fast, more reliable, and cost-effective validation of prostate cancer sequencing assays - saving the user time and money to achieve their quality assurance goals faster and allowing the user to assess the performance of cfDNA assays.
Technical data
Format: cfDNA
Genes covered: TP53, AR, PIK3CA, RB1, CDKN2A, STK11, PTEN, BRCA1, BRCA2
Allelic frequencies: 0.3% - 10%
Buffer: Tris-EDTA (10mM Tris-HCl, 1mM EDTA), pH 8.0
Product information
Fragment size: 160 bp
Unit size: 350 ng per vial
Concentration: 20 ng/µl
Verified mutations:
| Gene | DNA sequence change | Amino acid change | Expected allelic frequency (%) |
|---|---|---|---|
| TP53 | c.992A>G | p.Q331R | 0.60 |
| TP53 | c.742C>T | p.R248W | 9.00 |
| TP53 | c.668C>T | p.P223L | 0.50 |
| TP53 | c.820G>T | p.V274F | 1.00 |
| TP53 | c.414_del | p.K139Rfs*31 | 10.00 |
| AR | c.2623C>T | p.H875Y | 0.30 |
| AR | c.2623A>G | p.T878A | 0.30 |
| PIK3CA | c.1637A>G | p.Q546R | 0.70 |
| PIK3CA | c.1624G>A | p.E542K | 1.20 |
| RB1 | c.2143A>T | p.K715* | 1.00 |
| CDKN2A | c.250G>T | p.D84Y | 0.60 |
| STK11 | c.532_536del | p.KP178Gfs*86 | 1.20 |
| PTEN | c.17_18del | p.K6Rfs*4 | 0.50 |
| BRCA1 | c.5329dup c.5263_5264insC |
p.Q1777Pfs*74 p.Q1756Pfs*74 |
0.40 |
| BRCA2 | c.9924C>G | p.Y3308* | 0.40 |
| AR | Gain | Gain | 4.00 Copies |
| PTEN | Loss | Loss | 0.34 Copies |
General information
Storage: 4°C
Expiration: See all product shelf life information
Quality control
Fragmentation size: D1000 DNA ScreenTape assay
Allelic frequency: Droplet Digital™ PCR
Quantification: Qubit® dsDNA BR assay (Invitrogen)
Intended use: For assay developers and molecular diagnostic labs for routine performance monitoring of molecular biology assays. Research use only. Not for diagnostic procedures.
We accept orders using the following methods.
Online
Our online catalog and ordering system can be used to search our full menu of available Reference Standards. Select your desired reference standards and add them to the shopping basket. Your order can be submitted instantly using credit card, telephone ordering or a purchase order number as the preferred payment method.
Offline
If you prefer to send us orders outside our online ordering system, please see the Contact Us page for telephone, fax, and email details in order to place an order. We recommend that you use our online system to identify the products you require and their respective “HD” product codes.
To order offline we will require the following information:
- Product code(s) of the item(s) you wish to order (e.g. "HD123")
- Your name, email address, title and organization
- Shipping address and billing address with contact names
- Purchase Order number if you have one
- Telephone number
- VAT Number (European Countries only)
If you’re having trouble ordering or finding what you’re looking for, or if you require something we don’t yet offer, please contact us.
Additional Resources
Selection guides
Reference Standards
-
Do you have a wild-type control in the same background as the Prostate Cancer Panel cfDNA Reference Standard (HD836)?
-
How are Horizon cfDNA Reference Standards different from other circulating tumor DNA controls?
-
How are Horizon cfDNA Reference Standards fragmented?
-
What are cfDNA Reference Standards?
-
Which Droplet Digital PCR (ddPCR) system is used for variant detection at Horizon?
Related Products
The Prostate Cancer Panel cfDNA Reference Standard (Negative Control) is a well characterized, cell line-derived control material manufactured under ISO:13485 that is negative for 15 variants across 9 genes clinically relevant to prostate cancer.